Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer

Table 2 Number of tumor nodules, volume of ascites, body weight, frequency of hydronephrosis and mitotic index in the mice treated with bevacizumab and the untreated mice

Treatment	n	Tumor nodules	Ascites (mL)	Body weight (g)	Hydronephrosis		Mitosis index
					Right kidney	Left kidney
Non-therapy	5	16.64 ± 5.061	0.60 ± 0.512	12.21 ± 0.513	4 (80)	2 (40)	21.0 ± 5.7b
Therapy	5	17.66 ± 3.45	0.04 ± 0.03	12.41 ± 0.61	2 (40)	1 (20)	9.6 ± 2.1

¹P = 0.783;

²P = 0.042;

³P = 0.591;

^bP < 0.01 vs therapy group.